46 results on '"Glynne-Jones, R"'
Search Results
2. Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial
3. Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study
4. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
5. Should the RAPIDO schedule represent standard of care in locally advanced rectal cancer?
6. Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
7. Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial
8. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control
9. Adding extra dimensions in rectal cancer theory
10. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
11. Neoadjuvant chemotherapy in MRI-staged high-risk rectal cancer in addition to or as an alternative to preoperative chemoradiation?
12. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials
13. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
14. O-4 Average cumulative relative dose of adjuvant chemotherapy is more important than average relative dose intensity for colorectal cancer survival, with implications for treating obese patients: The OCTOPUS consortium
15. Adjuvant chemotherapy for rectal cancer after preoperative radiation or chemoradiation: One size does not fit all
16. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013
17. Anal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
18. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer
19. Reply to the letter to the editor: DPD testing in radical chemoradiation for anal squamous cell carcinoma? by R. Muirhead, H. Jones, D. Gilbert, A. Gilbert & C. Jacobs
20. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
21. Alternative clinical end points in rectal cancer—are we getting closer?
22. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?
23. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer
24. To PET or not to PET? That is the question. Staging in anal cancer
25. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010
26. SO-14 Baseline diffusion-weighted magnetic resonance imaging features to predict recurrence of anal squamous cell carcinoma following chemoradiotherapy
27. Adjuvant chemotherapy for rectal cancer
28. A phase Ib study of E7046 (AN0025) in combination with radiotherapy/chemoradiotherapy (RT/CRT) in preoperative treatment of rectal cancer
29. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007
30. Extending the interval to surgery in rectal cancer and filling the time with chemotherapy—how much is enough?
31. Definitive chemoradiotherapy in oesophageal cancer: treatment outcomes from a regional cancer centre
32. Corrections to “Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
33. InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial
34. Droplet digital PCR of circulating tumour DNA for the detection of RAS/BRAF mutation in metastatic colorectal cancer
35. Identifying patients who may benefit from oxaliplatin-containing perioperative chemo(radio)therapy for rectal cancer
36. Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis
37. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
38. 540P - A phase Ib study of E7046 (AN0025) in combination with radiotherapy/chemoradiotherapy (RT/CRT) in preoperative treatment of rectal cancer
39. LBA21 - InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial
40. 542P - Droplet digital PCR of circulating tumour DNA for the detection of RAS/BRAF mutation in metastatic colorectal cancer
41. O-022 - Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis
42. The diagnosis and management of gastric cancer: Expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010
43. P-287 Is second line aflibercept and FOLFIRI a tolerable and useful down-staging schedule in Ras mutant advanced colorectal cancer in a real world environment?
44. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
45. P-124 - Definitive chemoradiotherapy in oesophageal cancer: treatment outcomes from a regional cancer centre.
46. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.